Healthcare giant Roche acquired online and digital diabetes monitor mySugr and is turning it into a leading global dietary aid.
We are excited about this agreement, as we will be able to offer seamlessly accessible patient solutions within an open platform to better respond to the unmet needs of people with diabetes.
Roche will improve the digital platform with the latest graphics, facts and figures and ensure it’s a useful tool to help manage the life-threatening condition.
The firm’s goal is “to make diabetes suck less” and to help the world population suffering with the chronic illness.
According to CDC, it is estimated that there are 29.1 million Americans currently suffering with the disease. The World Health Organization states that the global number of people suffering with diabetes has risen from 108 million in 1980 to 422 million in 2014.
Experts say that the increase in junk food, sugary drinks and bad diets has sent the health industry into a spin. The number of diabetes cases has increased dramatically and the cost for care far outweighs that of a healthier diet.
The ‘diabetes industry’, to pardon a rather crass term, is a multibillion dollar business. Roche is ensuring that they not only tap into this pot but also help to create a healthier global population.
Med City News says “the mySugr app will help guide users to enter relevant information on meals, exercise, glucose levels and mood. It automates tracking through connected devices and estimates HbA1c statistics.”
A “diabetes monster” avatar alerts users when they make a poor food choice based on their history, information, facts and glucose levels.
The app is so sophisticated that it can also be synced with the users’ medical team to help monitor their condition, and even help with insulin doses through a Blous calculator.
Providers Add Digital Services for Better Healthcare and Engagement
Roche’s acquisition has highlighted a trend among healthcare and pharmaceutical companies, where they will add services to their roster to help “support patient engagement both to quantify the effectiveness of their drugs and devices and to gain additional insight from its customer base.”
Following on from this sentiment, Roche said that the mySugr app will become an integral part of its new patient-centered digital health services platform in diabetes care. The firm added that the app purchase will help bolster its position in diabetes management.
“We are excited about this agreement, as we will be able to offer seamlessly accessible patient solutions within an open platform to better respond to the unmet needs of people with diabetes. Our aim is to support people with diabetes to spend more time in their ideal glucose target range and improve their quality of life,” Roland Diggelmann, Roche Diagnostics CEO, said. “Having partnered with mySugr since 2014, we see an excellent cultural fit, as both our companies are passionate about taking diabetes management to the next level and making a difference in managing diabetes,” he added.
The app currently has more than one million users, and execs are hoping to increase this number globally over the coming years.